Meeting
2018 Gastrointestinal Cancers Symposium
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study.
Authors
Guillem Argiles
Vall d’Hebron University Hospital Institute of Oncology, Barcelona, Spain
Guillem Argiles , Takayuki Yoshino , Atsushi Ohtsu , Robert J. Mayer , Robert Winkler , Nadia Amellal , Ronan Fougeray , Akira Kanehisa , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01607957
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 744)
DOI
10.1200/JCO.2018.36.4_suppl.744
Abstract #
744
Poster Bd #
J10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Codon-specific KRAS mutations predict overall survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
First Author: Joris van de Haar
Poster
2016 Gastrointestinal Cancers Symposium
Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
First Author: Atsushi Ohtsu
Poster
2015 ASCO Annual Meeting
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
First Author: Atsushi Ohtsu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
An ARCAD database nomogram for prognostic prediction of treatment refractory metastatic colorectal cancer.
First Author: Eiji Oki